{"text": "Supplementary Material\n\nSupplementary Table 1. Multiple regression analysis for the association between the SLCO1B1 388A>G polymorphism and the lipid-lowering effects from 4 weeks of simvastatin treatment Variable 388A>G N Change(%) Unadjusted Adjusted Mean\u00b1SD SE P Value SE P Value TC GG 283 -31.1\u00b18.8 AG 212 -31.7\u00b19.5 -0.006 0.008 0.475 -0.006 0.008 0.444 AA 47 -31.6\u00b17.5 -0.003 0.007 0.712 -0.003 0.007 0.662 GG+AG 495 -31.4\u00b19.1 AA 47 -31.6\u00b17.5 -0.002 0.014 0.855 -0.003 0.014 0.804 LDL-C GG 283 -40.7\u00b112.6 AG 212 -40.5\u00b112.0 0.003 0.011 0.817 0.002 0.011 0.838 AA 47 -39.5\u00b114.3 0.006 0.01 0.546 0.007 0.01 0.52 GG+AG 495 -40.6\u00b112.3 AA 47 -39.5\u00b114.3 0.011 0.019 0.561 0.011 0.019 0.564 TG GG 283 -22.0\u00b133.0 AG 212 -23.0\u00b134.4 -0.011 0.031 0.723 -0.012 0.03 0.704 AA 47 -24.7\u00b136.2 -0.014 0.026 0.608 -0.017 0.026 0.522 GG+AG 495 -22.4\u00b133.6 AA 47 -24.7\u00b136.2 -0.022 0.052 0.665 -0.029 0.051 0.568 HDL-C GG 283 -8.9\u00b116.9 AG 212 -11.3\u00b115.8 -0.024 0.015 0.106 -0.023 0.015 0.123 AA 47 -10.2\u00b114.4 -0.007 0.013 0.617 -0.006 0.013 0.643 GG+AG 495 -9.9\u00b116.5 AA 47 -10.2\u00b114.4 -0.003 0.025 0.913 -0.001 0.025 0.965 Adjusted for BMI, age, alcohol consumption and smoking. \n\nSupplementary Table 2. Multiple regression analysis for the association between the SLCO1B1 521T>C polymorphism and the lipid-lowering effects from four weeks of simvastatin treatment Variable 521T>C N Change(%) Unadjusted Adjusted Mean\u00b1SD SE P Value SE P Value TC TT 425 -31.9\u00b18.7 TC 113 -29.9\u00b19.6 0.02 0.009 0.037 0.02 0.009 0.037 CC 4 -21.6\u00b112.2 0.051 0.022 0.019 0.052 0.022 0.018 CC+TC 117 -29.6\u00b19.7 TT 425 -31.9\u00b18.7 -0.022 0.009 0.016 -0.023 0.009 0.016 LDL-C TT 425 -41.2\u00b112.4 TC 113 -38.3\u00b112.7 0.029 0.013 0.03 0.029 0.013 0.026 CC 4 -29.6\u00b116.3 0.058 0.031 0.062 0.059 0.031 0.06 CC+TC 117 -38.0\u00b112.8 TT 425 -41.2\u00b112.4 -0.032 0.013 0.015 -0.033 0.013 0.013 TG TT 425 -22.8\u00b133.9 TC 113 -22.2\u00b133.4 0.006 0.036 0.864 0.004 0.036 0.907 CC 4 -9.7\u00b140.0 0.066 0.085 0.442 0.056 0.085 0.507 CC+TC 117 -21.8\u00b133.5 TT 425 -22.8\u00b133.9 -0.01 0.035 0.768 -0.008 0.035 0.828 HDL-C TT 425 -10.1\u00b116.3 TC 113 -8.9\u00b116.3 0.012 0.017 0.501 0.009 0.017 0.594 CC 4 -19.2\u00b113.9 -0.045 0.041 0.268 -0.054 0.04 0.181 CC+TC 117 -9.3\u00b116.3 TT 425 -10.1\u00b116.3 -0.008 0.017 0.634 -0.005 0.017 0.752 Adjusted for BMI, age, alcohol consumption and smoking. \n\nSupplementary Table 3. Multiple Regression analysis to analyze gene-gene joint associations with the lipid-lowering effects from four weeks of simvastatin treatment. 388A>G 521T>C N Change(%) Unadjusted Adjusted Mean\u00b1SD SE P Value SE P Value TC GG+AG CC+TC 116 -29.5\u00b19.8 - - - - - - GG+AG TT 379 -31.9\u00b18.8 -0.024 0.01 0.013 -0.024 0.01 0.014 AA CC+TC 1 - - - - - - - AA TT 46 -31.4\u00b17.5 -0.006 0.005 0.236 -0.007 0.005 0.178 LDL-C GG+AG CC+TC 116 -37.9\u00b112.8 - - - - - - GG+AG TT 379 -41.4\u00b112.1 -0.035 0.013 0.007 -0.036 0.013 0.006 AA CC+TC 1 - - - - - - - AA TT 46 -39.2\u00b114.3 -0.004 0.008 0.574 -0.005 0.008 0.492 TG GG+AG CC+TC 116 -21.7\u00b133.6 - - - - - - GG+AG TT 379 -22.6\u00b133.6 -0.009 0.036 0.798 -0.004 0.036 0.909 AA CC+TC 1 - - - - - - - AA TT 46 -24.5\u00b136.6 -0.009 0.02 0.641 -0.01 0.02 0.635 HDL-C GG+AG CC+TC 116 -9.2\u00b116.3 - - - - - - GG+AG TT 379 -10.1\u00b116.6 -0.01 0.018 0.585 -0.008 0.017 0.665 AA CC+TC 1 - - - - - - - AA TT 46 -9.9\u00b114.4 -0.002 0.009 0.794 -0.002 0.009 0.815 Adjusted for BMI, age, alcohol consumption and smoking. \n\nSupplementary Table 4. Multiple regression analysis for the association between the SLCO1B1 388A>G polymorphism and the lipid-lowering effects from eight weeks of simvastatin treatment Variable 388A>G N Change(%) Unadjusted Adjusted Mean\u00b1SD SE P Value SE P Value TC GG 283 -29.4\u00b19.7 AG 212 -30.5\u00b110.4 -0.011 0.009 0.241 -0.012 0.009 0.181 AA 47 -32.4\u00b18.5 -0.015 0.008 0.05 -0.015 0.008 0.048 GG+AG 495 -29.9\u00b110.0 AA 47 -32.4\u00b18.5 -0.025 0.015 0.099 -0.026 0.015 0.088 TG GG 283 -19.7\u00b131.7 AG 212 -18.7\u00b144.8 0.01 0.034 0.771 0.009 0.035 0.804 AA 47 -25.9\u00b127.5 -0.031 0.025 0.21 -0.032 0.025 0.193 GG+AG 495 -19.3\u00b137.8 AA 47 -25.9\u00b127.5 -0.066 0.057 0.244 -0.068 0.057 0.233 HDL-C GG 283 -13.0\u00b117.6 AG 212 -13.4\u00b118.3 -0.004 0.016 0.802 -0.003 0.016 0.869 AA 47 -18.1\u00b118.6 -0.026 0.014 0.068 -0.024 0.014 0.079 GG+AG 495 -13.2\u00b117.9 AA 47 -18.1\u00b118.6 -0.049 0.027 0.072 -0.048 0.027 0.074 LDL-C GG 283 -35.6\u00b115.5 AG 212 -36.2\u00b114.9 -0.006 0.014 0.649 -0.009 0.014 0.535 AA 47 -36.4\u00b112.7 -0.004 0.012 0.729 -0.004 0.012 0.711 GG+AG 495 -35.8\u00b115.2 AA 47 -36.4\u00b112.7 -0.006 0.023 0.808 -0.006 0.023 0.779 Change(%) = (serum lipid levels after 8 weeks treatment serum lipid levels at baseline)/serum lipid levels at baseline \n\n Supplementary Table 5. Multiple regression analysis for the association between the SLCO1B1 521T>C polymorphism and the lipid-lowering effects from eight weeks of simvastatin treatment Variable 521T>C N Change(%) Unadjusted Adjusted Mean\u00b1SD SE P Value SE P Value TC TT 425 -30.2\u00b110.0 TC 113 -29.7\u00b110.4 0.006 0.011 0.598 0.005 0.011 0.621 CC 4 -28.3\u00b12.2 0.01 0.025 0.694 0.012 0.025 0.618 CC+TC 117 -29.6\u00b110.2 TT 425 -30.2\u00b110.0 -0.006 0.01 0.561 -0.006 0.01 0.572 TG TT 425 -20.7\u00b136.1 TC 113 -17.1\u00b140.8 0.035 0.039 0.372 0.032 0.04 0.413 CC 4 -11.4\u00b127.5 0.046 0.091 0.609 0.044 0.091 0.626 CC+TC 117 -16.9\u00b140.4 TT 425 -20.7\u00b136.1 -0.037 0.039 0.338 -0.034 0.039 0.382 HDL-C TT 425 -13.8\u00b118.3 TC 113 -12.9\u00b117.1 0.01 0.019 0.22 0.008 0.019 0.673 CC 4 -16.0\u00b17.9 -0.011 0.046 0.812 -0.017 0.045 0.701 CC+TC 117 -13.0\u00b116.8 TT 425 -13.8\u00b118.3 -0.009 0.019 0.648 -0.007 0.019 0.724 LDL-C TT 425 -35.9\u00b115.3 TC 113 -36.0\u00b114.5 -0.001 0.016 0.93 -0.001 0.016 0.973 CC 4 -34.0\u00b16.0 0.009 0.038 0.806 0.017 0.038 0.65 CC+TC 117 -36.0\u00b114.3 TT 425 -35.9\u00b115.3 0.001 0.016 0.964 -0.001 0.016 0.969 Change(%) = (serum lipid levels after 8 weeks treatment serum lipid levels at baseline)/serum lipid levels at baseline \n\nSupplementary Table 6. Multiple Regression analysis to analyze gene-gene joint associations with the lipid-lowering effects from eight weeks of simvastatin treatment. 388A>G 521T>C N Change(%) Unadjusted Adjusted Mean\u00b1SD SE P Value SE P Value TC GG+AG CC+TC 116 -29.6\u00b110.2 GG+AG TT 379 -30.0\u00b110.0 -0.004 0.011 0.74 -0.003 0.011 0.758 AA CC\u00b1TC 1 AA TT 46 -32.4\u00b18.6 -0.009 0.006 0.104 -0.009 0.006 0.101 TG GG+AG CC+TC 116 -16.8\u00b140.5 - - - - - - GG+AG TT 379 -20.0\u00b137.0 -0.032 0.04 0.429 -0.028 0.041 0.497 AA CC+TC 1 - - - - - - - AA TT 46 -25.8\u00b127.8 -0.03 0.022 0.17 -0.025 0.022 0.255 HDL-C GG+AG CC+TC 116 -12.9\u00b116.9 - - - - - - GG+AG TT 379 -13.3\u00b118.2 -0.004 0.019 0.833 -0.003 0.019 0.881 AA CC+TC 1 - - - - - - - AA TT 46 -18.1\u00b118.8 -0.017 0.01 0.088 -0.015 0.01 0.132 LDL-C GG+AG CC+TC 116 -35.9\u00b114.3 - - - - - - GG+AG TT 379 -35.8\u00b115.5 0.001 0.016 0.069 - 0.016 0.998 AA CC+TC 1 - - - - - - - AA TT 46 -36.4\u00b112.9 -0.001 0.008 0.859 -0.003 0.008 0.702 Change(%) = (serum lipid levels after 8 weeks treatment serum lipid levels at baseline)/serum lipid levels at baseline \n\nSupplementary Table 7. Association between the 388A>G and 521T>C polymorphisms and the elevation of CK levels after four and eight weeks of simvastatin treatment CK N Baseline 4 weeks of ChangeA P1 8 weeks of ChangeB P2 levels treatment treatment 388A>G AA 47 119.83\u00b151.79 136.81\u00b176.16 16.98\u00b149.88 0.024 197.05\u00b1132.78 77.22\u00b1116.81 p<0.001 AG 212 108.35\u00b149.71 140.90\u00b1111.44 32.55\u00b187.00 p<0.001 173.70\u00b1137.16 65.34\u00b1113.49 p<0.001 GG 283 102.16\u00b143.50 127.80\u00b168.51 25.64\u00b157.19 p<0.001 157.85\u00b1110.30 55.69\u00b196.13 p<0.001 521T>C TT 425 107.83\u00b147.81 134.60\u00b189.39 26.77\u00b170.90 p<0.001 170.68\u00b1128.96 62.85\u00b1110.66 p<0.001 TC 113 99.47\u00b143.12 128.80\u00b183.38 29.33\u00b165.63 p<0.001 152.72\u00b1101.27 53.25\u00b181.23 p<0.001 CC 4 111.50\u00b154.02 176.75\u00b1135.84 65.25\u00b191.90 0.251 240.00\u00b1123.76 128.50\u00b177.61 0.045 P1:paired student t test was used to compare CK levels before and after four weeks of simvastatin treatment. P2:paired student t test was used to compare CK levels before and after eight weeks of simvastatin treatment. Achange = CK levels after 4 weeks treatment serum CK levels at baseline Bchange = CK levels after 8 weeks treatment serum CK levels at baseline \n\nSupplementary Table 8. Association between the SLCO1B1 388A>G polymorphism and CK response after four and eight consecutive weeks of treatment with simvastatin. Variable 388A>G N Change(%) Unadjusted adjusted Mean\u00b1SD SE P Value SE P Value CK elevation at 4 weeks GG 283 25.6\u00b157.2 AG 212 32.5\u00b187.0 6.907 6.493 0.288 6.477 6.44 0.315 AA 47 17.0\u00b149.9 -4.33 4.428 0.329 -4.35 4.486 0.333 CK elevation at 8 weeks GG 283 55.7\u00b196.1 AG 212 65.3\u00b1113.5 9.655 9.439 0.307 9.817 9.417 0.298 AA 47 77.2\u00b1116.8 10.766 7.819 0.169 11.048 8.027 0.17 Adjusted for: age, sex, BMI, smoking, and alcohol consumption. Change(%) = (serum CK levels after 4 or 8 weeks treatment serum CK levels at baseline)/serum CK levels at baseline \n\nSupplementary Table 9. Association between the SLCO1B1 521T>C polymorphism and CK response after four and eight consecutive weeks of treatment with simvastatin. Variable 521T>C N Change(%) Unadjusted adjusted Mean\u00b1SD SE P Value SE P Value CK elevation at 4 weeks TT 425 26.8\u00b170.9 TC 113 29.3\u00b165.6 2.552 7.391 0.73 2.745 7.391 0.711 CC 4 65.3\u00b191.9 19.238 17.851 0.282 22.058 17.676 0.213 CK elevation at 8 weeks TT 425 62.8\u00b1110.7 TC 113 53.3\u00b181.2 -9.593 11.134 0.389 -8.469 11.231 0.451 CC 4 128.5\u00b177.6 32.827 27.744 0.234 35.142 27.83 0.207 Adjusted for: age, sex, BMI, smoking, and alcohol consumption. Change (%) = (serum CK levels after 4 or 8 weeks treatment serum CK levels at baseline)/serum CK levels at baseline "}